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Abstract
Recent advances in genome engineering technologies based on the CRISPR-associated RNA-
guided endonuclease Cas9 are enabling the systematic interrogation of mammalian genome 
function. Analogous to the search function in modern word processors, Cas9 can be guided to 
specific locations within complex genomes by a short RNA search string. Using this system, DNA 
sequences within the endogenous genome and their functional outputs are now easily edited or 
modulated in virtually any organism of choice. Cas9-mediated genetic perturbation is simple and 
scalable, empowering researchers to elucidate the functional organization of the genome at the 
systems level and establish causal linkages between genetic variations and biological phenotypes. 
In this Review, we describe the development and applications of Cas9 for a variety of research or 
translational applications while highlighting challenges as well as future directions. Derived from 
a remarkable microbial defense system, Cas9 is driving innovative applications from basic biology 
to biotechnology and medicine.
Introduction
The development of recombinant DNA technology in the 1970s marked the beginning of a 
new era for biology. For the first time, molecular biologists gained the ability to manipulate 
DNA molecules, making it possible to study genes and harness them to develop novel 
medicine and biotechnology. Recent advances in genome engineering technologies are 
sparking a new revolution in biological research. Rather than studying DNA taken out of the 
context of the genome, researchers can now directly edit or modulate the function of DNA 
sequences in their endogenous context in virtually any organism of choice, enabling them to 
elucidate the functional organization of the genome at the systems level, as well as identify 
causal genetic variations.
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Broadly speaking, genome engineering refers to the process of making targeted 
modifications to the genome, its contexts (e.g., epigenetic marks), or its outputs (e.g., 
transcripts). The ability to do so easily and efficiently in eukaryotic and especially 
mammalian cells holds immense promise to transform basic science, biotechnology, and 
medicine (Figure 1).
For life sciences research, technologies that can delete, insert, and modify the DNA 
sequences of cells or organisms enable dissecting the function of specific genes and 
regulatory elements. Multiplexed editing could further allow the interrogation of gene or 
protein networks at a larger scale. Similarly, manipulating transcriptional regulation or 
chromatin states at particular loci can reveal how genetic material is organized and utilized 
within a cell, illuminating relationships between the architecture of the genome and its 
functions. In biotechnology, precise manipulation of genetic building blocks and regulatory 
machinery also facilitates the reverse engineering or reconstruction of useful biological 
systems, for example, by enhancing biofuel production pathways in industrially relevant 
organisms or by creating infection-resistant crops. Additionally, genome engineering is 
stimulating a new generation of drug development processes and medical therapeutics. 
Perturbation of multiple genes simultaneously could model the additive effects that underlie 
complex polygenic disorders, leading to new drug targets, while genome editing could 
directly correct harmful mutations in the context of human gene therapy (Tebas et al., 2014).
Eukaryotic genomes contain billions of DNA bases and are difficult to manipulate. One of 
the breakthroughs in genome manipulation has been the development of gene targeting by 
homologous recombination (HR), which integrates exogenous repair templates that contain 
sequence homology to the donor site (Figure 2A) (Capecchi, 1989). HR-mediated targeting 
has facilitated the generation of knockin and knockout animal models via manipulation of 
germline competent stem cells, dramatically advancing many areas of biological research. 
However, although HR-mediated gene targeting produces highly precise alterations, the 
desired recombination events occur extremely infrequently (1 in 106–109 cells) (Capecchi, 
1989), presenting enormous challenges for large-scale applications of gene-targeting 
experiments.
To overcome these challenges, a series of programmable nuclease-based genome editing 
technologies have been developed in recent years, enabling targeted and efficient 
modification of a variety of eukaryotic and particularly mammalian species. Of the current 
generation of genome editing technologies, the most rapidly developing is the class of RNA-
guided endonucleases known as Cas9 from the microbial adaptive immune system CRISPR 
(clustered regularly interspaced short palindromic repeats), which can be easily targeted to 
virtually any genomic location of choice by a short RNA guide. Here, we review the 
development and applications of the CRISPR-associated endonuclease Cas9 as a platform 
technology for achieving targeted perturbation of endogenous genomic elements and also 
discuss challenges and future avenues for innovation.
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Programmable Nucleases as Tools for Efficient and Precise Genome 
Editing
A series of studies by Haber and Jasin (Rudin et al., 1989; Plessis et al., 1992; Rouet et al., 
1994; Choulika et al., 1995; Bibikova et al., 2001; Bibikova et al., 2003) led to the 
realization that targeted DNA double-strand breaks (DSBs) could greatly stimulate genome 
editing through HR-mediated recombination events. Subsequently, Carroll and 
Chandrasegaran demonstrated the potential of designer nucleases based on zinc finger 
proteins for efficient, locus-specific HR (Bibikova et al., 2001, 2003). Moreover, it was 
shown in the absence of an exogenous homology repair template that localized DSBs can 
induce insertions or deletion mutations (indels) via the error-prone nonhomologous end-
joining (NHEJ) repair pathway (Figure 2A) (Bibikova et al., 2002). These early genome 
editing studies established DSB-induced HR and NHEJ as powerful pathways for the 
versatile and precise modification of eukaryotic genomes.
To achieve effective genome editing via introduction of site-specific DNA DSBs, four major 
classes of customizable DNA-binding proteins have been engineered so far: meganucleases 
derived from microbial mobile genetic elements (Smith et al., 2006), zinc finger (ZF) 
nucleases based on eukaryotic transcription factors (Urnov et al., 2005; Miller et al., 2007), 
transcription activator-like effectors (TALEs) from Xanthomonas bacteria (Christian et al., 
2010; Miller et al., 2011; Boch et al., 2009; Moscou and Bogdanove, 2009), and most 
recently the RNA-guided DNA endonuclease Cas9 from the type II bacterial adaptive 
immune system CRISPR (Cong et al., 2013; Mali et al., 2013a).
Meganuclease, ZF, and TALE proteins all recognize specific DNA sequences through 
protein-DNA interactions. Although meganucleases integrate its nuclease and DNA-binding 
domains, ZF and TALE proteins consist of individual modules targeting 3 or 1 nucleotides 
(nt) of DNA, respectively (Figure 2B). ZFs and TALEs can be assembled in desired 
combinations and attached to the nuclease domain of FokI to direct nucleolytic activity 
toward specific genomic loci. Each of these platforms, however, has unique limitations.
Meganucleases have not been widely adopted as a genome engineering platform due to lack 
of clear correspondence between meganuclease protein residues and their target DNA 
sequence specificity. ZF domains, on the other hand, exhibit context-dependent binding 
preference dueto crosstalk between adjacent modules when assembled into a larger array 
(Maeder et al., 2008). Although multiple strategies have been developed to account for these 
limitations (Gonzaelz et al., 2010; Sander et al., 2011), assembly of functional ZFPs with the 
desired DNA binding specificity remains a major challenge that requires an extensive 
screening process. Similarly, although TALE DNA-binding monomers are for the most part 
modular, they can still suffer from context-dependent specificity (Juillerat et al., 2014), and 
their repetitive sequences render construction of novel TALE arrays labor intensive and 
costly.
Given the challenges associated with engineering of modular DNA-binding proteins, new 
modes of recognition would significantly simplify the development of custom nucleases. 
The CRISPR nuclease Cas9 is targeted by a short guide RNA that recognizes the target 
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DNA via Watson-Crick base pairing (Figure 2C). The guide sequence within these CRISPR 
RNAs typically corresponds to phage sequences, constituting the natural mechanism for 
CRISPR antiviral defense, but can be easily replaced by a sequence of interest to retarget the 
Cas9 nuclease. Multiplexed targeting by Cas9 can now be achieved at unprecedented scale 
by introducing a battery of short guide RNAs rather than a library of large, bulky proteins. 
The ease of Cas9 targeting, its high efficiency as a site-specific nuclease, and the possibility 
for highly multiplexed modifications have opened up a broad range of biological 
applications across basic research to biotechnology and medicine.
The utility of customizable DNA-binding domains extends far beyond genome editing with 
site-specific endonucleases. Fusing them to modular, sequence-agnostic functional effector 
domains allows flexible recruitment of desired perturbations, such as transcriptional 
activation, to a locus of interest (Xu and Bestor, 1997; Beerli et al., 2000a; Konermann et 
al., 2013; Maeder et al., 2013a; Mendenhall et al., 2013). In fact, any modular enzymatic 
component can, in principle, be substituted, allowing facile additions to the genome 
engineering toolbox. Integration of genome- and epigenome-modifying enzymes with 
inducible protein regulation further allows precise temporal control of dynamic processes 
(Beerli et al., 2000b; Konermann et al., 2013).
CRISPR-Cas9: From Yogurt to Genome Editing
The recent development of the Cas9 endonuclease for genome editing draws upon more than 
a decade of basic research into understanding the biological function of the mysterious 
repetitive elements now known as CRISPR (Figure 3), which are found throughout the 
bacterial and archaeal diversity. CRISPR loci typically consist of a clustered set of CRISPR-
associated (Cas) genes and the signature CRISPR array—a series of repeat sequences (direct 
repeats) interspaced by variable sequences (spacers) corresponding to sequences within 
foreign genetic elements (protospacers) (Figure 4). Whereas Cas genes are translated into 
proteins, most CRISPR arrays are first transcribed as a single RNA before subsequent 
processing into shorter CRISPR RNAs (crRNAs), which direct the nucleolytic activity of 
certain Cas enzymes to degrade target nucleic acids.
The CRISPR story began in 1987. While studying the iap enzyme involved in isozyme 
conversion of alkaline phosphatase in E. coli, Nakata and colleagues reported a curious set 
of 29 nt repeats downstream of the iap gene (Ishino et al., 1987). Unlike most repetitive 
elements, which typically take the form of tandem repeats like TALE repeat monomers, 
these 29 nt repeats were interspaced by five intervening 32 nt nonrepetitive sequences. Over 
the next 10 years, as more microbial genomes were sequenced, additional repeat elements 
were reported from genomes of different bacterial and archaeal strains. Mojica and 
colleagues eventually classified interspaced repeat sequences as a unique family of clustered 
repeat elements present in >40% of sequenced bacteria and 90% of archaea (Mojica et al., 
2000).
These early findings began to stimulate interest in such microbial repeat elements. By 2002, 
Jansen and Mojica coined the acronym CRISPR to unify the description of microbial 
genomic loci consisting of an interspaced repeat array (Jansen et al., 2002; Barrangou and 
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van der Oost, 2013). At the same time, several clusters of signature CRISPR-associated 
(cas) genes were identified to be well conserved and typically adjacent to the repeat 
elements (Jansen et al., 2002), serving as a basis for the eventual classification of three 
different types of CRISPR systems (types I–III) (Haft et al., 2005; Makarova et al., 2011b). 
Types I and III CRISPR loci contain multiple Cas proteins, now known to form complexes 
with crRNA (CASCADE complex for type I; Cmr or Csm RAMP complexes for type III) to 
facilitate the recognition and destruction of target nucleic acids (Brouns et al., 2008; Hale et 
al., 2009) (Figure 4). In contrast, the type II system has a significantly reduced number of 
Cas proteins. However, despite increasingly detailed mapping and annotation of CRISPR 
loci across many microbial species, their biological significance remained elusive.
A key turning point came in 2005, when systematic analysis of the spacer sequences 
separating the individual direct repeats suggested their extrachromosomal and phage-
associated origins (Mojica et al., 2005; Pourcel et al., 2005; Bolotin et al., 2005). This 
insight was tremendously exciting, especially given previous studies showing that CRISPR 
loci are transcribed (Tang et al., 2002) and that viruses are unable to infect archaeal cells 
carrying spacers corresponding to their own genomes (Mojica et al., 2005). Together, these 
findings led to the speculation that CRISPR arrays serve as an immune memory and defense 
mechanism, and individual spacers facilitate defense against bacteriophage infection by 
exploiting Watson-Crick base-pairing between nucleic acids (Mojica et al., 2005; Pourcel et 
al., 2005). Despite these compelling realizations that CRISPR loci might be involved in 
microbial immunity, the specific mechanism of how the spacers act to mediate viral defense 
remained a challenging puzzle. Several hypotheses were raised, including thoughts that 
CRISPR spacers act as small RNA guides to degrade viral transcripts in a RNAi-like 
mechanism (Makarova et al., 2006) or that CRISPR spacers direct Cas enzymes to cleave 
viral DNA at spacer-matching regions (Bolotin et al., 2005).
Working with the dairy production bacterial strain Streptococcus thermophilus at the food 
ingredient company Danisco, Horvath and colleagues uncovered the first experimental 
evidence for the natural role of a type II CRISPR system as an adaptive immunity system, 
demonstrating a nucleic-acid-based immune system in which CRISPR spacers dictate target 
specificity while Cas enzymes control spacer acquisition and phage defense (Barrangou et 
al., 2007). A rapid series of studies illuminating the mechanisms of CRISPR defense 
followed shortly and helped to establish the mechanism as well as function of all three types 
of CRISPR loci inadaptive immunity. By studying the type I CRISPR locus of Escherichia 
coli, van der Oost and colleagues showed that CRISPR arrays are transcribed and converted 
into small crRNAs containing individual spacers to guide Cas nuclease activity (Brouns et 
al., 2008). In the same year, CRISPR-mediated defense by a type III-A CRISPR system 
from Staphylococcus epidermidis was demonstrated to block plasmid conjugation, 
establishing the target of Cas enzyme activity as DNA rather than RNA (Marraffini and 
Sontheimer, 2008), although later investigation of a different type III-B system from 
Pyrococcus furiosus also revealed crRNA-directed RNA cleavage activity (Hale et al., 2009, 
2012).
As the pace of CRISPR research accelerated, researchers quickly unraveled many details of 
each type of CRISPR system (Figure 4). Building on an earlier speculation that protospacer 
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adjacent motifs (PAMs) may direct the type II Cas9 nuclease to cleave DNA (Bolotin et al., 
2005), Moineau and colleagues highlighted the importance of PAM sequences by 
demonstrating that PAM mutations in phage genomes circumvented CRISPR interference 
(Deveau et al., 2008). Additionally, for types I and II, the lack of PAM within the direct 
repeat sequence within the CRISPR array prevents self-targeting by the CRISPR system. In 
type III systems, however, mismatches between the 5′ end of the crRNA and the DNA target 
are required for plasmid interference (Marraffini and Sontheimer, 2010).
By 2010, just 3 years after the first experimental evidence for CRISPR in bacterial 
immunity, the basic function and mechanisms of CRISPR systems were becoming clear. A 
variety of groups had begun to harness the natural CRISPR system for various 
biotechnological applications, including the generation of phage-resistant dairy cultures 
(Quiberoni et al., 2010) and phylogenetic classification of bacterial strains (Horvath et al., 
2008, 2009). However, genome editing applications had not yet been explored.
Around this time, two studies characterizing the functional mechanisms of the native type II 
CRISPR system elucidated the basic components that proved vital for engineering a simple 
RNA-programmable DNA endonuclease for genome editing. First, Moineau and colleagues 
used genetic studies in Streptococcus thermophilus to reveal that Cas9 (formerly called 
Cas5, Csn1, or Csx12) is the only enzyme within the cas gene cluster that mediates target 
DNA cleavage (Garneau et al., 2010). Next, Charpentier and colleagues revealed a key 
component in the biogenesis and processing of crRNA in type II CRISPR systems—a 
noncoding trans-activating crRNA (tracrRNA) that hybridizes with crRNA to facilitate 
RNA-guided targeting of Cas9 (Deltcheva et al., 2011). This dual RNA hybrid, together 
with Cas9 and endogenous RNase III, is required for processing the CRISPR array transcript 
into mature crRNAs (Deltcheva et al., 2011). These two studies suggested that there are at 
least three components (Cas9, the mature crRNA, and tracrRNA) that are essential for 
reconstituting the type II CRISPR nuclease system. Given the increasing importance of 
programmable site-specific nucleases based on ZFs and TALEs for enhancing eukaryotic 
genome editing, it was tantalizing to think that perhaps Cas9 could be developed into an 
RNA-guided genome editing system. From this point, the race to harness Cas9 for genome 
editing was on.
In 2011, Siksnys and colleagues first demonstrated that the type II CRISPR system is 
transferrable, in that transplantation of the type II CRISPR locus from Streptococcus 
thermophilus into Escherichia coli is able to reconstitute CRISPR interference in a different 
bacterial strain (Sapranauskas et al., 2011). By 2012, biochemical characterizations by the 
groups of Charpentier, Doudna, and Siksnys showed that purified Cas9 from Streptococcus 
thermophilus or Streptococcus pyogenes can be guided by crRNAs to cleave target DNA in 
vitro (Jinek et al., 2012; Gasiunas et al., 2012), in agreement with previous bacterial studies 
(Garneau et al., 2010; Deltcheva et al., 2011; Sapranauskas et al., 2011). Furthermore, a 
single guide RNA (sgRNA) can be constructed by fusing a crRNA containing the targeting 
guide sequence to a tracrRNA that facilitates DNA cleavage by Cas9 in vitro (Jinek et al., 
2012).
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In 2013, a pair of studies simultaneously showed how to successfully engineer type II 
CRISPR systems from Streptococcus thermophilus (Cong et al., 2013) and Streptococcus 
pyogenes (Cong et al., 2013; Mali et al., 2013a) to accomplish genome editing in 
mammalian cells. Heterologous expression of mature crRNA-tracrRNA hybrids (Cong et al., 
2013) as well as sgRNAs (Cong et al., 2013; Mali et al., 2013a) directs Cas9 cleavage within 
the mammalian cellular genome to stimulate NHEJ or HDR-mediated genome editing. 
Multiple guide RNAs can also be used to target several genes at once. Since these initial 
studies, Cas9 has been used by thousands of laboratories for genome editing applications in 
a variety of experimental model systems (Sander and Joung, 2014). The rapid adoption of 
the Cas9 technology was also greatly accelerated through a combination of open-source 
distributors such as Addgene, as well as a number of online user forums such as http://
www.genome-engineering.org and http://www.egenome.org.
Structural Organization and Domain Architecture of Cas9
The family of Cas9 proteins is characterized by two signature nuclease domains, RuvC and 
HNH, each named based on homology to known nuclease domain structures (Figure 2C). 
Though HNH is a single nuclease domain, the full RuvC domain is divided into three 
subdomains across the linear protein sequence, with RuvC I near the N-terminal region of 
Cas9 and RuvC II/III flanking the HNH domain near the middle of the protein. Recently, a 
pair of structural studies shed light on the structural mechanism of RNA-guided DNA 
cleavage by Cas9.
First, single-particle EM reconstructions of the Streptococcus pyogenes Cas9 (SpCas9) 
revealed a large structural rearrangement between apo-Cas9 unbound to nucleic acid and 
Cas9 in complex with crRNA and tracrRNA, forming a central channel to accommodate the 
RNA-DNA heteroduplex (Jinek et al., 2014). Second, a high-resolution structure of SpCas9 
in complex with sgRNA and the complementary strand of target DNA further revealed the 
domain organization to comprise of an α-helical recognition (REC) lobe and a nuclease 
(NUC) lobe consisting of the HNH domain, assembled RuvC subdomains, and a PAM-
interacting (PI) C-terminal region (Nishimasu et al., 2014) (Figure 5A and Movie S1).
Together, these two studies support the model that SpCas9 unbound to target DNA or guide 
RNA exhibits an autoinhibited conformation in which the HNH domain active site is 
blocked by the RuvC domain and is positioned away from the REC lobe (Jinek et al., 2014). 
Binding of the RNA-DNA heteroduplex would additionally be sterically inhibited by the 
orientation of the C-terminal domain. Asaresult, apo-Cas9 likely cannot bind nor cleave 
target DNA. Like many ribonucleoprotein complexes, the guide RNA serves as a scaffold 
around which Cas9 can fold and organize its various domains (Nishimasu et al., 2014).
The crystal structure of SpCas9 incomplex with an sgRNA and target DNA also revealed 
how the REC lobe facilitates target binding. An arginine-rich bridge helix (BH) within the 
REC lobe is responsible for contacting the 3′ 8–12 nt of the RNA-DNA heteroduplex 
(Nishimasu et al., 2014), which correspond with the seed sequence identified through guide 
sequence mutation experiments (Jinek et al., 2012; Cong et al., 2013; Fu et al., 2013; Hsu et 
al., 2013; Pattanayak et al., 2013; Mali et al., 2013b).
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The SpCas9 structure also provides a useful scaffold for engineering or refactoring of Cas9 
and sgRNA. Because the REC2 domain of SpCas9 is poorly conserved in shorter orthologs, 
domain recombination or truncation is a promising approach for minimizing Cas9 size. 
SpCas9 mutants lacking REC2 retain roughly 50% of wild-type cleavage activity, which 
could be partly attributed to their weaker expression levels (Nishimasu et al., 2014). 
Introducing combinations of orthologous domain recombination, truncation, and peptide 
linkers could facilitate the generation of a suite of Cas9 mutant variants optimized for 
different parameters such as DNA binding, DNA cleavage, or overall protein size.
Metagenomic, Structural, and Functional Diversity of Cas9
Cas9 is exclusively associated with the type II CRISPR locus and serves as the signature 
type II gene. Based on the diversity of associated Cas genes, type IICRISPR loci are further 
subdivided into three subtypes (IIA–IIC) (Figure 5B) (Makarova et al., 2011a; Chylinski et 
al., 2013). Type II CRISPR loci mostly consist of the cas9, cas1, and cas2 genes, as well as 
a CRISPR array and tracrRNA. Type IIC CRISPR systems contain only this minimal set of 
cas genes, whereas types IIA and IIB have an additional signature csn2 or cas4 gene, 
respectively (Chylinski et al., 2013).
Subtype classification of type II CRISPR loci is based on the architecture and organization 
of each CRISPR locus. For example, type IIA and IIB loci usually consist of four cas genes, 
whereas type IIC loci only contain three cas genes. However, this classification does not 
reflect the structural diversity of Cas9 proteins, which exhibit sequence homology and 
length variability irrespective of the subtype classification of their parental CRISPR locus. 
Of >1,000 Cas9 nucleases identified from sequence databases (UniProt) based on homology, 
protein length israther heterogeneous, roughly ranging from 900 to 1600 amino acids 
(Figure 5C). The length distribution of most Cas9 proteins can be divided into two 
populations centered around 1,100 and 1,350 amino acids in length. It is worth noting that a 
third population of large Cas9 proteins belonging to subtype IIA, formerly called Csx12, 
typically contain around 1500 amino acids.
Despite the apparent diversity of protein length, all Cas9 proteins share similar domain 
architecture (Makarova et al., 2011a; Chylinski et al., 2013, 2014; Fonfara et al., 2014), 
consisting of the RuvC and HNH nuclease domains and the REC domain, an α-helix-rich 
region with an Arg-rich bridge helix. Unlike type I and III CRISPR systems, which are 
found in both bacteria and archaea, type II CRISPRs have so far only been found in bacterial 
strains (Chylinski et al., 2013). The majority of Cas9 orthologs in fact belong to the phyla of 
Bacteroidetes, Proteobacteria, and Firmicutes (Figure 5D).
The length difference among Cas9 proteins largely results from variable conservation of the 
REC domain (Figure 5E), which associates with the sgRNA and target DNA. For example, 
the type IIC Actinomyces naeslundii Cas9, which is more compact than its Streptococcus 
pyogenes ortholog, has a much smaller REC lobe with substantially different orientation 
(Jinek et al., 2014).
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Protospacer Adjacent Motif: Cas9 Target Range and Search Mechanism
A critical feature of the Cas9 system is the protospacer-adjacent motif (PAM), which flanks 
the 3′ end of the DNA target site (Figure 2C) and dictates the DNA target search mechanism 
of Cas9. In addition to facilitating self versus non-self discrimination by Cas9 (Shah et al., 
2013), because direct repeats do not contain PAM sites, biochemical and structural 
characterization of SpCas9 suggested that PAM recognition is involved in triggering the 
transition between Cas9 target binding and cleavage conformations (Sternberg et al., 2014; 
Jinek et al., 2014; Nishimasu et al., 2014).
Single-molecule imaging indicated that Cas9-crRNA-tracrRNA complexes first associate 
with PAM sequences throughout the genome, allowing Cas9 to initiate DNA strand 
separation via unknown mechanisms (Sternberg et al., 2014). DNA competitor cleavage 
assays additionally suggested that formation of the RNA-DNA heteroduplex is initiated at 
the PAM site before proceeding PAM distally by interrogating the target site upstream of the 
PAM for guide sequence complementarity (Sternberg et al., 2014). Binding of the PAM and 
a matching target then triggers Cas9 nuclease activity by activating the HNH and RuvC 
domains, supported by the observation of HNH domain flexibility within the Cas9-sgRNA-
DNA ternary complex (Nishimasu et al., 2014).
The complexity of the PAM sequences also determines the overall DNA targeting space of 
Cas9. For example, the 5′-NGG of SpCas9 allows it to target, on average, every 8 bp within 
the human genome (Cong et al., 2013; Hsu et al., 2013). Additionally, SpCas9 can target 
sites flanked by 5′-NAG PAMs (Jiang et al., 2013; Hsu et al., 2013), albeit at a lower 
efficiency, further expanding its editing versatility. The PAM is specific to each Cas9 
ortholog, even within the same species, such as 5′-NNA GAAW for Streptococcus 
thermophilus CRISPR1 (Deveau et al., 2008) and 5′-NGGNG for Streptococcus 
thermophilus CRISPR3 (Horvath et al., 2008). Another Cas9 from Neisseria meningitidis 
with a 5′-NNNNGATT PAM requirement (Zhang et al., 2013) was recently applied in 
human pluripotent stem cells (Hou et al., 2013).
Computational (Chylinski et al., 2013, 2014; Fonfara et al., 2014) or metagenomic analysis 
of bacteria and archaea containing CRISPR loci could lead to the discovery of Cas9 
nucleases with additional PAMs to expand the targeting range of the Cas9 toolkit. Delivery 
of multiple Cas9 proteins with different PAM requirements facilitates orthogonal genome 
engineering, in which independent but simultaneous functions are applied at different loci 
within the same cell or cell population. NmCas9 and SpCas9, for example, can be employed 
for independent transcriptional repression and nuclease activity (Esvelt et al., 2013).
PAM specificity can also be modified. For instance, orthologous replacement of the PAM-
interacting (PI) domain from the Streptococcus thermophilus CRISPR3 Cas9 with the 
corresponding domain from Streptococcus pyogenes Cas9 successfully altered PAM 
recognition from 5′-NGGNG to 5′-NGG (Nishimasu et al., 2014). PAM engineering 
strategies could also be exploited to generate short Cas9 orthologs with flexible 5′-NGG or 
5′-NG PAM domains.
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Genome Editing Using CRISPR-Cas9 in Eukaryotic Cells
To date, the Streptococcus pyogenes Cas9 (SpCas9) has been used broadly to achieve 
efficient genome editing in a variety of species and cell types, including human cell lines, 
bacteria, zebrafish, yeast, mouse, fruit fly, roundworm, rat, common crops, pig, and monkey 
(see Sander and Joung [2014] for a detailed list). SpCas9 is also dramatically expanding the 
catalog of genetically tractable model organisms, for example, by enabling the introduction 
of multiplex mutations in cynomolgus monkeys (Niu et al., 2014).
SpCas9 can be targeted either with a pair of crRNA and tracrRNA (Cong et al., 2013) or 
with a chimeric sgRNA (Cong et al., 2013; Mali et al., 2013a; Cho et al., 2013; Jinek et al., 
2013), as the crRNA or sgRNA contains a 20 nt guide sequence that directly matches the 
target site. The only requirement for the selection of Cas9 target sites is the presence of a 
protospacer-adjacent motif (PAM) immediately downstream of the target site.
An early discrepancy in the use of SpCas9 editing of the human genome was the drastically 
higher levels of NHEJ-induced indels given the same target site, when using the engineered 
dual guide RNA system (Cong et al., 2013) compared to the engineered sgRNA(+48) 
scaffold, which only contained up to the 48th base of tracrRNA. Although sgRNA(+48) is 
sufficient for cleaving DNA in vitro (Jinek et al., 2012), extension of the 3′ tracrRNA 
sequence preserved several hairpin structures (sgRNA(+72) and sgRNA(+84)) that were 
critical for effective sgRNA-mediated genome editing in vivo (Mali et al., 2013a; Hsu et al., 
2013). The additional stem loops enhance the stability of the sgRNA (Hsu et al., 2013) and 
are important for proper Cas9-sgRNA-DNA ternary complex formation (Nishimasu et al., 
2014). These analyses of the sgRNA structure and function indicate that careful sgRNA 
design is critical for optimal Cas9 activity, especially for testing novel Cas9 candidates 
derived from metagenomic analysis.
One hallmark of the natural CRISPR-Cas9 system is its inherent ability to efficiently cleave 
multiple distinct target sequences in parallel (Barrangou et al., 2007; Garneau et al., 2010) 
by converting a pre-crRNA transcript containing many spacers into individual guide RNAs 
duplexes (mature crRNA and tracrRNA) through hybridization with tracrRNA (Deltcheva et 
al., 2011). Harnessing this unique aspect of CRISPR interference would enable highly 
scalable multiplex perturbations. Indeed, coexpression of a CRISPR array containing 
spacers targeting different genes (Cong et al., 2013) or a battery of several sgRNAs (Mali et 
al., 2013a; Wang et al., 2013) together with SpCas9 has led to efficient multiplex editing in 
mammalian cells. Surprisingly, CRISPR arrays containing direct repeats interspaced by 
designer spacers were processed into mature guide RNAs without the introduction of 
bacterial RNase III. Because RNase III is required for crRNA maturation in prokaryotic 
cells (Deltcheva et al., 2011), it is likely that endogenous mammalian RNases play 
compensatory roles (Cong et al., 2013).
Specificity of Cas9 Nucleases
Because genome editing leads to permanent modifications within the genome, the targeting 
specificity of Cas9 nucleases is of particular concern, especially for clinical applications and 
gene therapy. A combination of in vitro and in vivo assays has been typically used to 
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characterize the specificity of ZFNs and TALENs (Gabriel et al., 2011), but systematic 
analysis has remained challenging due to difficulties in synthesizing large libraries of 
proteins with varying sequence specificity. However, Cas9 target recognition is dictated by 
the Watson-Crick base-pairing interactions of an RNA guide with its DNA target, enabling 
experimentally tractable and systematic evaluation of the effect of guide RNA-target DNA 
mismatches on Cas9 activity.
Streptococcus pyogenes Cas9 specificity has been extensively characterized by multiple 
groups using mismatched guide RNA libraries, in vitro selection, and reporter assays (Fu et 
al., 2013; Hsu et al., 2013; Mali et al., 2013b; Pattanayak et al., 2013). In contrast to 
previous studies that suggested a seed sequence model for Cas9 specificity, wherein the first 
8–12 PAM-proximal guide sequence bases determine specificity (Jinek et al., 2012; Cong et 
al., 2013), these studies collectively demonstrate that Cas9 tolerates mismatches throughout 
the guide sequence in a manner that is sensitive to the number, position, and distribution of 
the mismatches (Fu et al., 2013; Hsu et al., 2013; Mali et al., 2013b; Pattanayak et al., 2013). 
Although the PAM-distal bases of the guide sequence are less important for specificity, 
meaning that mismatches at those positions often do not abolish Cas9 activity, all positions 
within the guide contribute to overall specificity. Importantly, off-target sites followed by 
the 5′-NAG PAM can also lead to off-target cleavage, demonstrating the importance of 
considering both NGG and NAG PAMs in off-target analysis.
Interestingly, Cas9 requires extensive homology between the guide RNA and target DNA in 
order to cleave but can remain semi-transiently bound with only a short stretch of 
complementary sequence between the guide RNA and target DNA. These observations 
suggest that Cas9 has many off-target binding sites but cleaves only a small fraction of them 
(Wu et al., 2014). Thus, concerns about off-target activity could vary widely given a desired 
application that exploits Cas9 for its DNA binding or cleavage capabilities.
Enzymatic concentration is also an important factor in determining Cas9 off-target 
mutagenesis. This is particularly important because Cas9 can tolerate even five mismatches 
within the target site (Fu et al., 2013). Mismatches appear to be better tolerated when Cas9 is 
present at high concentrations (Hsu et al., 2013; Pattanayak et al., 2013), leading to higher 
off-target activity; decreasing Cas9 concentration significantly improves the on- to off-target 
ratio at the expense of the efficiency of on-target cleavage (Hsu et al., 2013). The duration of 
Cas9 expression is likely an additional factor that tunes off-target activity, though its 
contributions remain to be carefully investigated.
While potential off-target sites have typically been computationally determined by searching 
for genomic sequences with high sequence similarity to the desired target locus, 
wholegenome sequencing or other unbiased ways of labeling DNA DSBs genome-wide may 
illuminate off-target sites that are not predictable by first-order sequence comparison. 
Unbiased genome-wide characterizations have been previously used to characterize ZFN 
off-target mutagenesis (Gabriel et al., 2011) and could easily be adapted for Cas9 nuclease 
activity. Such data, perhaps in combination with thermodynamic characterization of guide 
RNA and target DNA hybridization, will likely provide a quantitative framework for 
assessing and predicting the off-target activity of Cas9. Multiple groups now provide Cas9 
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target selection tools (e.g., http://tools.genome-engineering. org, http://zifit.partners.org, and 
http://www.e-crisp.org).
Improving Cas9 Target Recognition Fidelity
Cas9 nucleases cleave DNA through the activity of their RuvC and HNH nuclease domains, 
each of which nicks a strand of DNA to generate a blunt-ended DSB (Figure 2C). SpCas9 
can be converted into a DNA “nickase” that creates a single-stranded break (SSB) by 
catalytically inactivating the RuvC or HNH nuclease domains (Gasiunas et al., 2012; Jinek 
et al., 2012; Sapranauskas et al., 2011) via point mutations (Figure 6A). Because DNA 
single-strand breaks are repaired via the high-fidelity base excision repair (BER) pathway 
(Dianov and Hübscher, 2013), Cas9 nickases can be exploited for more specific NHEJ as 
well as HR.
To improve on-target DSB specificity, a double-nicking approach analogous to dimeric 
ZFNs or TALENs can be used to increase the overall number of bases that are specifically 
recognized in the target DNA. Using pairs of guide RNAs (Mali et al., 2013b; Ran et al.,
2013)and an SpCas9 HNH+/RuvC− nickase mutant (D10A), properly spaced cooperative 
nicks can mimic DSBs and mediate efficient indel formation (Figure 6B). Because off-target 
nick sites are precisely repaired, this multiplexed nicking strategy can improve specificity by 
up to 1,500× relative to the wild-type Cas9 (Ran et al., 2013).
Because Cas9 nuclease or multiplex nicking activity both stimulate NHEJ, a population of 
cells cotargeted with a homology donor would eventually possess a mix of indel mutants 
and donor integrants. Single DNA nicks, however, are also able to mediate donor 
recombination, albeit at a lower level than with DSBs (Hsu et al., 2013). Cas9 nickases with 
single sgRNAs can thus be used to mediate HR rather than NHEJ. Furthermore, off-target 
integration is highly unlikely due to long homology arms flanking the donor cassette.
In addition to the double-nicking strategy, sgRNAs truncated by 2 or 3 nt have been reported 
to significantly increase targeting specificity of SpCas9, potentially due to greater mismatch 
sensitivity (Fu et al., 2014). These truncated sgRNAs can be combined with multiplex 
nicking to further reduce off-target mutagenesis (Fu et al., 2014). Future structure-function 
analyses and Cas9 and protein engineering via rational design or directed evolution may lead 
to further improvements in Cas9 specificity.
Applications of Cas9 in Research, Medicine, and Biotechnology
Cas9 can be used to facilitate a wide variety of targeted genome engineering applications. 
The wild-type Cas9 nuclease has enabled efficient and targeted genome modification in 
many species that have been intractable using traditional genetic manipulation techniques. 
The ease of retargeting Cas9 by simply designing a short RNA sequence also enables large-
scale unbiased genome perturbation experiments to probe gene function or elucidate causal 
genetic variants. In addition to facilitating co-valent genome modifications, the wild-type 
Cas9 nuclease can also be converted into a generic RNA-guided homing device (dCas9) by 
inactivating the catalytic domains. The use of effector fusions can greatly expand the 
repertoire of genome engineering modalities achievable using Cas9. For example, a variety 
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of proteins or RNAs can be tethered to Cas9 or sgRNA to alter transcription states of 
specific genomic loci, monitor chromatin states, or even rearrange the three-dimensional 
organization of the genome.
Rapid Generation of Cellular and Animal Models
Cas9-mediated genome editing has enabled accelerated generation of transgenic models and 
expands biological research beyond traditional, genetically tractable animal model 
organisms (Sander and Joung, 2014). By recapitulating genetic mutations found in patient 
populations, CRISPR-based editing could be used to rapidly model the causal roles of 
specific genetic variations instead of relying on disease models that only phenocopy a 
particular disorder. This could be applied to develop novel transgenic animal models (Wang 
et al., 2013; Niu et al., 2014), to engineer isogenic ES and iPS cell disease models with 
specific mutations introduced or corrected, respectively, or in vivo and ex vivo gene 
correction (Schwank et al., 2013; Wu et al., 2013).
For generation of cellular models, Cas9 can be easily introduced into the target cells using 
transient transfection of plasmids carrying Cas9 and the appropriately designed sgRNA 
(Figure 6C). Additionally, the multiplexing capabilities of Cas9 offer a promising approach 
for studying common human diseases—such as diabetes, heart disease, schizophrenia, and 
autism—that are typically polygenic. Large-scale genome-wide association studies 
(GWAS), for example, have identified haplotypes that show strong association with disease 
risk. However, it is often difficult to determine which of several genetic variants in tight 
linkage disequilibrium with the haplotype or which of several genes in the region are 
responsible for the phenotype. Using Cas9, one could study the effect of each individual 
variant or test the effect of manipulating each individual gene on an isogenic background by 
editing stem cells and differentiating them into cell types of interest.
For generation of transgenic animal models, Cas9 protein and transcribed sgRNA can be 
directly injected into fertilized zygotes to achieve heritable gene modification at one or 
multiple alleles in models such as rodents and monkeys (Wang et al., 2013; Li et al., 2013; 
Yang et al., 2013; Niu et al., 2014) (Figure 6D). By bypassing the typical ES cell targeting 
stage in generating transgenic lines, the generation time for mutant mice and rats can be 
reduced from more than a year to only several weeks. Such advances will facilitate cost-
effective and large-scale in vivo mutagenesis studies in rodent models and can be combined 
with highly specific editing (Fu et al., 2014; Ran et al., 2013) to avoid confounding off-
target mutagenesis. Successful multiplex targeting in cynomolgus monkey models was also 
recently reported (Niu et al., 2014), suggesting the potential for establishing more accurate 
modeling of complex human diseases such as neuropsychiatric disorders using primate 
models. Additionally, Cas9 could be harnessed for direct modification of somatic tissue, 
obviating the need for embryonic manipulation (Figure 6E) as well as enabling therapeutic 
use for gene therapy.
One outstanding challenge with transgenic animal models generated via zygotic injection of 
CRISPR reagents is genetic mosaicism, partly due to a slow rate of nuclease-induced 
mutagenesis. Studies to date have typically relied on the injection of Cas9 mRNA into 
zygotes (fertilized embryos at the single-cell stage). However, because transcription and 
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translation activity is suppressed in the mouse zygote, Cas9 mRNA translation into active 
enzymatic form is likely delayed until after the first cell division (Oh et al., 2000). Because 
NHEJ-mediated repair is thought to introduce indels of random length, this translation delay 
likely plays a major role in contributing to genetic mosaicism in CRISPR-modified mice. To 
overcome this limitation, Cas9 protein and sgRNA could be directly injected into single-cell 
fertilized embryos. The high rate of nonmutagenic repair by the NHEJ process may 
additionally contribute to undesired mosaicism because introducing indels that mutate the 
Cas9 recognition site would then have to compete with zygotic division rates. To increase 
the mutagenic activity of NHEJ, a pair of sgRNAs flanking a small fragment of the target 
gene may be used to increase the probability of gene disruption.
Functional Genomic Screens
The efficiency of genome editing with Cas9 makes it possible to alter many targets in 
parallel, thereby enabling unbiased genome-wide functional screens to identify genes that 
play an important role in a phenotype of interest. Lentiviral delivery of sgRNAs directed 
against all genes (either together with Cas9 or to cells already expressing Cas9) can be used 
to perturb thousands of genomic elements in parallel. Recent papers have demonstrated the 
ability to perform robust negative and positive selection screens in human cells (Wang et al., 
2014; Shalem et al., 2014) by introducing loss-of-function mutations into early, constitutive 
coding exons of a different gene in each cell (Figure 6F). Genome-wide loss-of-function 
screens have previously used RNAi, but this approach leads to only partial knockdown, has 
extensive off-target effects, and is limited to transcribed (and usually protein-coding) genes. 
By contrast, Cas9-mediated pooled sgRNA screens have been shown to provide increased 
screening sensitivity as well as consistency and can be designed to target nearly any DNA 
sequence (Shalem et al., 2014).
Future applications of single sgRNA libraries may also enable the perturbation of noncoding 
genetic elements, while multiplex sgRNA delivery may be used to dissect the function of 
large genomic regions through tiled microdeletions. For example, systematic targeting of 
gene regulatory regions could facilitate the discovery of distant enhancers, general promoter 
architectures, and any additional regulatory elements that have an effect on protein levels. 
An additional application could be to dissect large, uncharacterized genomic regions that are 
implicated in sequencing studies or GWAS.
Tethering dCas9 to different effector domains may also facilitate genomic screens beyond 
loss-of-function phenotypes. dCas9 fused to epigenetic modifiers, for instance, could be 
used to study the effects of methylation or certain chromatin states on cellular differentiation 
or disease pathologies, whereas transcriptional activators allow screening for gain-of-
function phenotypes. Using truncated sgRNAs or building redundancy with several sgRNAs 
targeting each locus would be important design principles for filtering out false positive 
signals and improving the interpretability of screening data.
Transcriptional Modulation
dCas9 binding alone to DNA elements may repress transcription by sterically hindering 
RNA polymerase machinery (Qi et al., 2013), likely by stalling transcriptional elongation. 
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This CRISPR-based interference, or CRISPRi, works efficiently in prokaryotic genomes but 
is less effective in eukaryotic cells (Gilbert et al., 2013). The repressive function of CRISPRi 
can be enhanced by tethering dCas9 to transcriptional repressor domains such as KRAB or 
SID effectors, which promote epigenetic silencing (Gilbert et al., 2013; Konermann et al., 
2013). However, dCas9-mediated transcriptional repression needs to be further improved—
in the current generation of dCas9-based eukaryotic transcription repressors, even the 
addition of helper functional domains results in only partial transcriptional knockdown 
(Gilbert et al., 2013; Konermann et al., 2013).
Cas9 can also be converted into a synthetic transcriptional activator by fusing it to VP16/
VP64 or p65 activation domains (Figure 6G). In general, targeting Cas9 activators with a 
single sgRNA to a particular endogenous gene promoter leads to only modest transcriptional 
upregulation (Konermann et al., 2013; Maeder et al., 2013b; Perez-Pinera et al., 2013; Mali 
et al., 2013b). By tiling a promoter with multiple sgRNAs, several groups have reported 
strong synergistic effects with nonlinear increases in activation (Perez-Pinera et al., 2013; 
Maeder et al., 2013b; Mali et al., 2013b). Although the requirement for multiple sgRNAs to 
achieve efficient transcription activation is potentially advantageous for increased 
specificity, screening applications employing libraries of sgRNAs will require highly 
efficient and specific transcriptional control using individual guide RNAs.
Epigenetic Control
Complex genome functions are defined by the highly dynamic landscape of epigenetic 
states. Epigenetic modifications that tune histones are thus crucial for transcriptional 
regulation and play important roles in a variety of biological functions. These marks, such as 
DNA methylation or histone acetylation, are established and maintained in mammalian cells 
by a variety of enzymes that are recruited to specific genomic loci either directly or 
indirectly through scaffolding proteins.
Previously, zinc finger proteins and TAL effectors have been used in a small number of 
proof-of-concept studies to achieve locus-specific targeting of epigenetic modifying 
enzymes (Beerli et al., 2000a; Konermann et al., 2013; Maeder et al., 2013a; Mendenhall et 
al., 2013). Cas9 epigenetic effectors (epiCas9s) that can artificially install or remove specific 
epigenetic marks at specific loci would serve as a more flexible platform to probe the causal 
effects of epigenetic modifications in shaping the regulatory networks of the genome (Figure 
6G). Of course, the potential for off-target activity or crosstalk between effector domains 
and endogenous epigenetic complexes would need to be carefully characterized. One 
solution could be to harness prokaryotic epigenetic enzymes to develop orthogonal 
epigenetic regulatory systems that minimize crosstalk with endogenous proteins.
Live Imaging of the Cellular Genome
The spatial organization of functional and structural elements within the cell contribute to 
the functional output of genomes, which can be amplified or suppressed dynamically. 
However, the way that genomes are modified and how their structural organization in vivo 
modulates functional output remain unclear. Genomic loci located megabases apart or on 
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entirely different chromosomes could be brought into close proximity given appropriate 
chromosomal organization, thus mediating long-range trans interactions.
Studying the interactions of specific genes given changing chromatin states would require a 
robust method to visualize DNA in living cells. Traditional techniques for labeling DNA, 
such as fluorescence in situ hybridization (FISH), require sample fixation and are thus 
unable to capture live processes. Fluorescently tagged Cas9 labeling of specific DNA loci 
was recently developed as a powerful live-cell-imaging alternative to DNA-FISH (Chen et 
al., 2013) (Figure 6H). Advances in orthogonal Cas9 proteins or modified sgRNAs will 
build out multi-color and multi-locus capabilities to enhance the utility of CRISPR-based 
imaging for studying complex chromosomal architecture and nuclear organization.
Inducible Regulation of Cas9 Activity
By exploiting the bilobed structure of Cas9, it may be possible to split the protein into two 
units and control their reassembly via small-molecule or light-inducible heterodimeric 
domains (Figure 6I). Small-molecule induction would facilitate systemic control of Cas9 in 
patients or animal models, whereas optical regulation enables more spatially precise 
perturbation. For example, the light-inducible dimerization domains CIB1 and CRY2 or 
chemically inducible analogs ABI and PYL, which have been successfully used to construct 
inducible TALEs (Konermann et al., 2013), may be adapted to engineer inducible Cas9 
systems.
Future Development of Cas9-Based Genome Engineering Technologies
Unbiased Analysis of Cas9 Binding and Cleavage
Despite the rapid adoption of Cas9 as a platform technology for genetic and epigenetic 
perturbation and significant progress in understanding and improving Cas9 specificity, its 
on- and off-target DNA binding and cleavage profiles still need to be thor oughly evaluated. 
Studies to date characterizing Cas9 off-target activity have relied on in silico computational 
prediction or in vitro selection. As a result, they have been unable to account for the 
likelihood of Cas9 activity that is unpredictable by sequence ho-mology to the sgRNA guide 
sequence.
Because the off-target activity of dCas9 binding for effector domain localization may be 
much more extensive than Cas9-mediated genome editing, unbiased profiling methods are 
needed to refine our understanding of “true positive” Cas9 off-target activity that actually 
leads to undesired functional outcomes. Cas9-based chromatin immunoprecipitation 
sequencing (ChIP-seq) analysis at multiple target sites could be a high-throughput solution 
for understanding binding degen eracy (Wu et al., 2014), whereas techniques for detecting 
and labeling double-strand breaks (Crosetto et al., 2013) will help to achieve a 
comprehensive map of Cas9-induced off-target indels.
These data together will help to generate predictive models for minimizing off-target 
activity in gene therapeutics or other applications requiring high levels of precision. 
Understanding Cas9 binding and cleavage in the context of chromatin accessibility and 
epigenetic states will also inform better computational evaluation of guide RNA specificity. 
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For example, particular sgRNAs could be evaluated based on the genomic nature of its off-
target sites, which would vary by guide sequence. Degenerate targeting of transcriptionally 
silent genes for a cell type or tissue of interest would likely be preferred to off-target sites in 
the coding region of essential housekeeping genes.
Although it is still unclear how Cas9 is affected by chromatin accessibility and 
heterochromatin versus euchromatin, dCas9 transcriptional activators can upregulate 
transcription at sites lacking DNase I hypersensitivity sites, indicating successful binding to 
inaccessible chromatin (Perez-Pinera et al., 2013) (Figure 6G). CpG methylation does not 
appear to affect DNA cleavage in vitro, and Cas9 could introduce indels at a highly 
methylated promoter in vivo (Hsu et al., 2013). It will be important to evaluate Cas9 binding 
and cleavage of genomic loci in relevant primary cells with different chromatin states, 
ideally in post-mitotic cells in which genomic architecture is stably defined.
Overall, these efforts aimed at improving our understanding of Cas9 binding and cleavage 
specificity will complement existing methods (Mali et al., 2013b; Ran et al., 2013; Fu et al., 
2014) as well as future protein engineering and metagenomic mining efforts to improve 
Cas9 specificity and the selection of guide RNA target sites.
Development of Versatile Delivery and Expression Systems for Applications of Cas9
Viral vectors such as adeno-associated virus (AAV) or lentivirus are commonly used for 
delivering genes of interest in vivo or into cell types resistant to common transfection 
methods, such as immune cells. AAV vectors have been commonly used for attractive 
candidates for efficient gene delivery in vivo because of their low immunogenic potential, 
reduced oncogenic risk from host-genome integration, and well-characterized serotype 
specificity (Figure 6E). However, the most commonly used Cas9 nuclease-encoding gene 
from Streptococcus pyogenes is >4 kb in length, which is difficult to transduce using AAV 
due to its 4.7 kb packaging capacity. Non-viral approaches for introducing CRISPR reagents 
in vivo present a fertile ground for developing novel delivery strategies, from liposomes and 
aptamers to cell-penetrating peptides and the molecular Trojan horse (Niewoehner et al., 
2014).
However, viral approaches are still highly desirable due to their low immunogenicity and 
wide array of characterized tropisms. The size constraints of viral vectors can be sidestepped 
by using significantly smaller Cas9 orthologs derived from metagenomic discovery, several 
of which have already been characterized and validated in human cells (Cong et al., 2013; 
Hou et al., 2013; Esvelt et al., 2013). Interestingly, short Cas9 variants reported to date 
recognize much longer PAM sequences than SpCas9 (5′-NNAGAAW from Streptococcus 
thermophilus CRISPR1 or 5′-NNNNGATT from Neisseria meningitidis) (Zhang et al., 
2013; Garneau et al., 2010), whereas some longer orthologs have more relaxed PAMs (5′-
NG from Francisella novicida) (Fonfara et al., 2014). Although the effect of PAM 
restriction on DNA targeting specificity remains to be investigated, the more limited overall 
targeting range of short Cas9 variants may be partially compensated for by decreasing the 
number of potential off-target substrates genome-wide.
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Moving beyond Endogenous Cellular Repair
The current generation of genome editing technologies depends on the endogenous DNA 
repair machinery to introduce loss-of-function mutations or precise modifications (Figure 
2A). Although Cas9 can be used to generate indel mutations via NHEJ with high efficiency, 
the absolute rate of HDR remains relatively low. Although it is sufficient for the generation 
of cell lines, especially when paired with drug selection or FACS enrichment, poor rates of 
recombination greatly limit the practical utility of Cas9-mediated targeted gene insertion in 
fertilized zygotes or somatic tissue. Homologous recombination proteins are also mainly 
expressed in the G2 phase of the cell cycle, making HDR-based gene editing difficult in 
postmitotic cells such as neurons or cardiac myocytes. As a result, methods for stimulating 
HDR-based repair or alternative strategies for efficient gene insertion are urgently needed. 
For instance, the highly efficient DNA damage repair system in Deinococcus radiodurans 
(Zahradka et al., 2006) may be exploited to enable efficient genome editing in mitotic as 
well as postmitotic cells.
Furthermore, the majority of CRISPR-based technology development has focused on the 
signature Cas9 nuclease from type II CRISPR systems. However, there remains a wide 
diversity of CRISPR types and functions. Cas RAMP module (Cmr) proteins identified in 
Pyrococcus furiosus and Sulfolobus solfataricus (Hale et al., 2012) constitute an RNA-
targeting CRISPR immune system, forming a complex guided by small CRISPR RNAs that 
target and cleave complementary RNA instead of DNA. Cmr protein homologs can be found 
throughout bacteria and archaea, typically relying on a 5′ site tag sequence on the target-
matching crRNA for Cmr-directed cleavage.
Unlike RNAi, whichis targeted largely by a 6 nt seed region and to a lesser extent 13 other 
bases, Cmr crRNAs contain 30–40 nt of target complementarity. Cmr-CRISPR technologies 
for RNA targeting are thus a promising target for orthogonal engineering and minimal off-
target modification. Although the modularity of Cmr systems for RNA-targeting in 
mammalian cells remains to be investigated, Cmr complexes native to P. furiosus have 
already been engineered to target novel RNA substrates (Hale et al., 2009, 2012).
Cas9 as a Therapeutic Molecule for Treating Genetic Disorders
Although Cas9 has already been widely used as a research tool, a particularly exciting future 
direction is the development of Cas9 as a therapeutic technology for treating genetic 
disorders. For a monogenic recessive disorder due to loss-of-function mutations (such as 
cystic fibrosis, sickle-cell anemia, or Duchenne muscular dystrophy), Cas9 may be used to 
correct the causative mutation. This has many advantages over traditional methods of gene 
augmentation that deliver functional genetic copies via viral vector-mediated overexpression
—particularly that the newly functional gene is expressed in its natural context. For 
dominant-negative disorders in which the affected gene is haplosufficient (such as 
transthyretin-related hereditary amyloidosis or dominant forms of retinitis pigmentosum), it 
may also be possible to use NHEJ to inactivate the mutated allele to achieve therapeutic 
benefit. For allele-specific targeting, one could design guide RNAs capable of distinguishing 
between single-nucleotide polymorphism (SNP) variations in the target gene, such as when 
the SNP falls within the PAM sequence.
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Some monogenic diseases also result from duplication of genomic sequences. For these 
diseases, the multiplexing capability of Cas9 may be exploited for deletion of the duplicated 
elements. For example, trinucleotide repeat disorders could be treated using two 
simultaneous DSBs to excise the repeat region. The success of this strategy will likely be 
higher for diseases such as Friedreich's ataxia, in which duplications occur in noncoding 
regions of the target gene, because NHEJ-mediated repair may lead to imperfect or 
frameshifted repair junctions.
In addition to repairing mutations underlying inherited disorders, Cas9-mediated genome 
editing might be used to introduce protective mutations in somatic tissues to combat 
nongenetic or complex diseases. For example, NHEJ-mediated inactivation of the CCR5 
receptor in lymphocytes (Lombardo et al., 2007) may be a viable strategy for circumventing 
HIV infection, whereas deletion of PCSK9 (Cohenet al., 2005) orangiopoietin (Musunuru et 
al., 2010) may provide therapeutic effects against statin-resistant hypercholesterolemia or 
hyperlipidemia. Although these targets may be also addressed using siRNA-mediated 
protein knockdown, a unique advantage of NHEJ-mediated gene inactivation is the ability to 
achieve permanent therapeutic benefit without the need for continuing treatment. As with all 
gene therapies, it will of course be important to establish that each proposed therapeutic use 
has a favorable benefit-risk ratio.
Cas9 could be used beyond the direct genome modification of somatic tissue, such as for 
engineering therapeutic cells. Chimeric antigen receptor (CAR) T cells can be modified ex 
vivo and reinfused into a patient to specifically target certain cancers (Couzin-Frankel, 
2013). The ease of design and testing of Cas9 may also facilitate the treatment of highly rare 
genetic variants through personalized medicine. Supporting these tremendous possibilities 
are a number of animal model studies as well as clinical trials using programmable 
nucleases that already provide important insights into the future development of Cas9-based 
therapeutics.
Recently, hydrodynamic delivery of plasmid DNA encoding Cas9 and sgRNA along with a 
repair template into the liver of an adult mouse model of tyrosinemia was shown to be able 
to correct the mutant Fah gene and rescue expression of the wild-type Fah protein in ∼1 out 
of 250 cells (Yin et al., 2014). In addition, clinical trials successfully used ZF nucleases to 
combat HIV infection by ex vivo knockout of the CCR5 receptor. In all patients, HIV DNA 
levels decreased, and in one out of four patients, HIV RNA became undetectable (Tebas et 
al., 2014). Both of these results demonstrate the promise of programmable nucleases as a 
new therapeutic platform.
However, numerous challenges still lie ahead. Most importantly, successful clinical 
translation will depend on appropriate and efficacious delivery systems to target specific 
disease tissues. To achieve high levels of therapeutic efficacy and simultaneously address a 
broad spectrum of genetic disorders, homologous recombination efficiency will need to be 
significantly improved. Although permanent genome modification has advantages over 
monoclonal antibody or siRNA treatments, which require repeated administration of the 
therapeutic molecule, the long-term implications remain unclear. As researchers further 
develop and test Cas9 toward clinical translation, it will be paramount to thoroughly 
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characterize the safety as well as physiological effects of Cas9 using a variety of preclinical 
models.
Conclusions
The story of how a mysterious prokaryotic viral defense system became one of the most 
powerful and versatile platforms for engineering biology highlights the importance of basic 
science research. Just as recombinant DNA technology benefited from basic investigation of 
the restriction enzymes that are central to warfare between phage and bacteria, the latest 
generation of Cas9-based genome engineering tools are also based on components from the 
microbial antiphage defense system. It is highly likely that the future solutions for efficient 
and precise gene modification will be found in as of yet unexplored corners of the rich 
biological diversity of nature.
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Figure 1. Applications of Genome Engineering
Genetic and epigenetic control of cells with genome engineering technologies is enabling a 
broad range of applications from basic biology to biotechnology and medicine. (Clockwise 
from top) Causal genetic mutations or epigenetic variants associated with altered biological 
function or disease phenotypes can now be rapidly and efficiently recapitulated in animal or 
cellular models (Animal models, Genetic variation). Manipulating biological circuits could 
also facilitate the generation of useful synthetic materials, such as algae-derived, silicabased 
diatoms for oral drug delivery (Materials). Additionally, precise genetic engineering of 
important agricultural crops could confer resistance to environmental deprivation or 
pathogenic infection, improving food security while avoiding the introduction of foreign 
DNA (Food). Sustainable and cost-effective biofuels are attractive sources for renewable 
energy, which could be achieved by creating efficient metabolic pathways for ethanol 
production in algae or corn (Fuel). Direct in vivo correction of genetic or epigenetic defects 
in somatic tissue would be permanent genetic solutions that address the root cause of 
genetically encoded disorders (Gene surgery). Finally, engineering cells to optimize high 
yield generation of drug precursors in bacterial factories could significantly reduce the cost 
and accessibility of useful therapeutics (Drug development).
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Figure 2. Genome Editing Technologies Exploit Endogenous DNA Repair Machinery
(A) DNA double-strand breaks (DSBs) are typically repaired by nonhomologous end-
joining (NHEJ) or homology-directed repair (HDR). In the error-prone NHEJ pathway, Ku 
heterodimers bind to DSB ends and serve as a molecular scaffold for associated repair 
proteins. Indels are introduced when the complementary strands undergo end resection and 
misaligned repair due to micro-homology, eventually leading to frameshift mutations and 
gene knockout. Alternatively, Rad51 proteins may bind DSB ends during the initial phase of 
HDR, recruiting accessory factors that direct genomic recombination with homology arms 
on an exogenous repair template. Bypassing the matching sister chromatid facilitates the 
introduction of precise gene modifications.
(B) Zinc finger (ZF) proteins and transcription activator-like effectors (TALEs) are naturally 
occurring DNA-binding domains that can be modularly assembled to target specific 
sequences. ZF and TALE domains each recognize 3 and 1 bp of DNA, respectively. Such 
DNA-binding proteins can be fused to the FokI endonuclease to generate programmable 
site-specific nucleases.
(C) The Cas9 nuclease from the microbial CRISPR adaptive immune system is localized to 
specific DNA sequences via the guide sequence on its guide RNA (red), directly base-
pairing with the DNA target. Binding of a protospacer-adjacent motif (PAM, blue) 
downstream of the target locus helps to direct Cas9-mediated DSBs.
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Figure 3. Key Studies Characterizing and Engineering CRISPR Systems
Cas9 has also been referred to as Cas5, Csx12, and Csn1 in literature prior to 2012. For 
clarity, we exclusively adopt the Cas9 nomenclature throughout this Review. CRISPR, 
clustered regularly interspaced short palindromic repeats; Cas, CRISPR-associated; crRNA, 
CRISPR RNA; DSB, double-strand break; tracrRNA, trans-activating CRISPR RNA.
Hsu et al. Page 28
Cell. Author manuscript; available in PMC 2015 February 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. Natural Mechanisms of Microbial CRISPR Systems in Adaptive Immunity
Following invasion of the cell by foreign genetic elements from bacteriophages or plasmids 
(step 1: phage infection), certain CRISPR-associated (Cas) enzymes acquire spacers from 
the exogenous protospacer sequences and install them into the CRISPR locus within the 
prokaryotic genome (step 2: spacer acquisition). These spacers are segregated between 
direct repeats that allow the CRISPR system to mediate self and nonself recognition. The 
CRISPR array is a noncoding RNA transcript that is enzymatically maturated through 
distinct pathways that are unique to each type of CRISPR system (step 3: crRNA biogenesis 
and processing).
In types I and III CRISPR, the pre-crRNA transcript is cleaved within the repeats by 
CRISPR-associated ribonucleases, releasing multiple small crRNAs. Type III crRNA 
intermediates are further processed at the 3′ end by yet-to-be-identified RNases to produce 
the fully mature transcript. In type II CRISPR, an associated trans-activating CRISPR RNA 
(tracrRNA) hybridizes with the direct repeats, forming an RNA duplex that is cleaved and 
processed by endogenous RNase III and other unknown nucleases. Maturated crRNAs from 
type I and III CRISPR systems are then loaded onto effector protein complexes for target 
recognition and degradation. In type II systems, crRNA-tracrRNA hybrids complex with 
Cas9 to mediate interference.
Both type I and III CRISPR systems use multiprotein interference modules to facilitate 
target recognition. In type I CRISPR, the Cascade complex is loaded with a crRNA 
molecule, constituting a catalytically inert surveillance complex that recognizes target DNA. 
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The Cas3 nuclease is then recruited to the Cascade-bound R loop, mediating target 
degradation. In type III CRISPR, crRNAs associate either with Csm or Cmr complexes that 
bind and cleave DNA and RNA substrates, respectively. In contrast, the type II system 
requires only the Cas9 nuclease to degrade DNA matching its dual guide RNA consisting of 
a crRNA-tracrRNA hybrid.
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Figure 5. Structural and Metagenomic Diversity of Cas9 Orthologs
(A) Crystal structure of Streptococcus pyogenes Cas9 in complex with guide RNA and 
target DNA.
(B) Canonical CRISPR locus organization from type II CRISPR systems, which can be 
classified into IIA-IIC based on their cas gene clusters. Whereas type IIC CRISPR loci 
contain the minimal set of cas9, cas1, and cas2, IIA and IIB retain their signature csn2 and 
cas4 genes, respectively.
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(C) Histogram displaying length distribution of known Cas9 orthologs as described in 
UniProt, HAMAP protein family profile MF_01480.
(D) Phylogenetic tree displaying the microbial origin of Cas9 nucleases from the type II 
CRISPR immune system. Taxonomic information was derived from greengenes 16S rRNA 
gene sequence alignment, and the tree was visualized using the Interactive Tree of Life tool 
(iTol).
(E) Four Cas9 orthologs from families IIA, IIB, and IIC were aligned by ClustalW 
(BLOSUM). Domain alignment is based on the Streptococcus pyogenes Cas9, whereas 
residues highlighted in red indicate highly conserved catalytic residues within the RuvC I 
and HNH nuclease domains.
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Figure 6. Applications of Cas9 as a Genome Engineering Platform
(A) The Cas9 nuclease cleaves DNA via its RuvC and HNH nuclease domains, each 
ofwhich nicks a DNA strand to generate blunt-end DSBs. Either catalytic domain can be 
inactivated to generate nickase mutants that cause single-strand DNA breaks.
(B) Two Cas9 nickase complexes with appropriately spaced target sites can mimic targeted 
DSBs via cooperative nicks, doubling the length of target recognition without sacrificing 
cleavage efficiency.
(C) Expression plasmids encoding the Cas9 gene and a short sgRNA cassette driven by the 
U6 RNA polymerase III promoter can be directly transfected into cell lines of interest.
(D) Purified Cas9 protein and in vitro transcribed sgRNA can be microinjected into 
fertilized zygotes for rapid generation of transgenic animal models.
(E) For somatic genetic modification, high-titer viral vectors encoding CRISPR reagents can 
be transduced into tissues or cells of interest.
(F) Genome-scale functional screening can be facilitated by mass synthesis and delivery of 
guide RNA libraries.
(G) Catalytically dead Cas9 (dCas9) can be converted into a general DNA-binding domain 
and fused to functional effectors such as transcriptional activators or epigenetic enzymes. 
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The modularity of targeting and flexible choice of functional domains enable rapid 
expansion of the Cas9 toolbox.
(H) Cas9 coupled to fluorescent reporters facilitates live imaging of DNA loci for 
illuminating the dynamics of genome architecture.
(I) Reconstituting split fragments of Cas9 via chemical or optical induction of heterodimer 
domains, such as the cib1/cry2 system from Arabidopsis, confers temporal control of 
dynamic cellular processes.
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